Showing 4801-4810 of 7764 results for "".
- Study: Risk of Indoor Tanning Dependency Highest in Women with Depressive Symptomshttps://practicaldermatology.com/news/study-risk-of-indoor-tanning-dependency-highest-in-women-with-depressive-symptoms/2458003/More than one in five young, white women who have used indoor tanning at least once in the past year show signs of being addicted to the high dose of ultraviolet (UV) radiation from tanning beds. In addition, women with symptoms of depression were three times more likely to meet the crite
- PruGen Pharmaceuticals Takes Action to Aid Hurricane Relief Effortshttps://practicaldermatology.com/news/prugen-pharmaceuticals-takes-action-to-aid-hurricane-relief-efforts/2458007/In the wake of several devastating and destructive hurricanes in the continental US and Puerto Rico, PruGen Pharmaceuticals is helping to those in need. The PruGen Foundation, a nonprofit organization founded by PruGen Pharmaceuticals and focused on philanthropic
- Timing of Melanoma Diagnosis, Treatment Can Mean Life or Deathhttps://practicaldermatology.com/news/timing-of-melanoma-diagnosis-treatment-can-mean-life-or-death/2458004/The sooner melanoma patients are treated, the better their survival, particularly for stage I melanoma, according to a new study from the Cleveland Clinic. The research appears online today in the Journal of the
- FDA Clears Xstrahl Photoelectric Therapy Systemhttps://practicaldermatology.com/news/fda-clears-xstrahl-photoelectric-therapy-system/2458005/Xstrahl has received FDA 510K clearance for the marketing of its latest skin cancer therapy device. The Photoelectric Therapy System is a compact and ergonomic superficial X-Ray therapy system operating in the 10kV to 80kV range intended for superficial radiotherapy and surface electronic brachyt
- Menlo Therapeutics Expands Management Teamhttps://practicaldermatology.com/news/menlo-therapeutics-expands-management-team/2458006/Menlo Therapeutics Inc., a late stage biopharmaceutical company, is developing a neurokinin 1 (NK‐1) receptor antagonist (serlopitant) for the treatment of pruritus associated with various underlying conditions, and for the treatment of refractory chronic cough. The company, which continues to ad
- Ortho Dermatologics: Long-term Efficacy Data for Siliqhttps://practicaldermatology.com/news/ortho-dermatologics-long-term-efficacy-data-for-siliq/2458009/Siliq™ (brodalumab) injection provided sustained high levels of skin clearance (PASI 100) over more than two years in patients with moderate-to-severe psoriasis, according to data presented at the 2017 Fall Clinical Dermatology Conference in Las Vegas and reported by
- FDA Approves Stelara for Treatment of Adolescents with Moderate To Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-stelara-for-treatment-of-adolescents-with-moderate-to-severe-plaque-psoriasis/2458010/The FDA approved an expanded indication for Janssen Biotech, Inc.'s Stelara (ustekinumab) for the treatment of adolescents (12 years of age or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. Today's approval marks a significant mile
- Eau Thermale Avène Expands its #AveneHope Programhttps://practicaldermatology.com/news/eau-thermale-avne-expands-its-avenehope-program/2458015/In recognition of Eczema Awareness Month and National Bullying Prevention Awareness Month this October, Eau Thermale Avène is expanding its #AveneHope program to
- ASDS Honors Top Choose Skin Health Skin Cancer Screenershttps://practicaldermatology.com/news/asds-honors-top-choose-skin-health-skin-cancer-screeners/2458021/The American Society for Dermatologic Surgery (ASDS) honored the top screeners in
- Two New Grants Continue Dr. Fredric S. Brandt's Legacyhttps://practicaldermatology.com/news/two-new-grants-continue-dr-fredric-s-brandts-legacy/2458018/Two American Society for Dermatologic Surgery members received grants totaling more tha